Drug intelligence / Profile preview

ipentidone

Development stage: Phase 3
Lead developer: CSPC Pharmaceutical Group
Modality: Small Molecules
Administration: Oral

Overview

Ipentidone is an atypical antipsychotic small molecule developed by CSPC Pharmaceutical Group (specifically its subsidiary CSPC Zhongqi Pharmaceutical Technology) for the treatment of schizophrenia. Structurally, it is a pentanone analog of iloperidone, characterized by a 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]pentan-1-one structure. Like other second-generation antipsychotics, ipentidone functions as a multi-receptor antagonist, primarily targeting the dopamine D2 and serotonin 5-HT2A receptors. It has been evaluated in Phase II clinical trials in China (e.g., CTR20140090), where its efficacy, safety, and tolerability were compared against risperidone in adult patients with schizophrenia.

Other names: 伊培酮

Targets

HTR2A (Serotonin receptor 5-HT2A)DRD2 (Dopamine D2 Receptor)

Beyond the preview

Go deeper on ipentidone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ipentidone.